5-Amino-1MQ Research Guide Ireland

Overview

5-Amino-1MQ is a small molecule, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in adipose tissue that methylates nicotinamide using S-adenosylmethionine (SAM) as a methyl donor. This enzymatic activity depletes cellular NAD+ and SAM pools. By inhibiting NNMT, 5-Amino-1MQ is hypothesised in preclinical research to increase intracellular NAD+ and SAM levels, which may in turn influence adipocyte metabolism and energy expenditure. It is important to note that 5-Amino-1MQ is a small molecule, not a peptide in the strict chemical sense, but it is catalogued and discussed alongside peptide research compounds due to its overlapping research use context. The compound sits at a very early stage of the research pipeline. NNMT was established as a credible anti-obesity and metabolic target through genetic knockdown studies, and 5-Amino-1MQ was subsequently developed as a pharmacological chemical probe to test the same hypothesis using small-molecule inhibition rather than gene silencing. Rodent studies using diet-induced obese mice report reductions in fat mass and improvements in metabolic markers without a corresponding decrease in food intake, distinguishing its proposed mechanism from appetite-suppression-based approaches. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✗ (no published human clinical trial data exists for 5-Amino-1MQ)
Observational	✗
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Mechanism of Action

5-Amino-1MQ works by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme abundantly expressed in white adipose tissue and, to a lesser extent, liver tissue. NNMT catalyses the methylation of nicotinamide, a reaction that consumes S-adenosylmethionine (SAM) as the methyl donor and produces 1-methylnicotinamide as a by-product. Because this reaction draws down both the SAM pool and the nicotinamide substrate (a precursor in NAD+ salvage pathways), high NNMT activity in adipocytes is associated with reduced intracellular NAD+ and SAM availability. By blocking NNMT catalytic activity, 5-Amino-1MQ is hypothesised to preserve or elevate intracellular NAD+ and SAM levels within adipocytes. Since NAD+ is a required cofactor for numerous metabolic enzymes, including sirtuins involved in energy metabolism regulation, researchers hypothesise that this shift could alter adipocyte energy handling in ways that reduce fat accumulation and improve markers of metabolic health. This proposed pathway remains a research hypothesis under investigation in preclinical models and has not been confirmed in human physiology.

Research Areas & Reported Effects

NNMT Inhibition & Adipose Tissue Metabolism

The foundational rationale for targeting NNMT in adipose tissue comes from genetic knockdown research showing that reducing NNMT expression in fat and liver tissue protected mice against diet-induced obesity. 5-Amino-1MQ was developed as a small-molecule tool to reproduce this effect pharmacologically, allowing researchers to inhibit NNMT enzymatic activity directly rather than silencing the gene. Research in this area focuses on characterising the degree and selectivity of NNMT inhibition achieved by the compound in cell-based assays and adipose tissue models.

Preclinical Fat Mass Findings (Rodent Models)

In diet-induced obese mouse studies, administration of 5-Amino-1MQ has been reported to reduce fat mass and body weight gain relative to untreated controls. Notably, these reductions have been reported without a corresponding decrease in food intake, which researchers interpret as evidence that the effect operates through altered adipocyte energy metabolism rather than appetite suppression. These findings remain confined to rodent models and have not been replicated in human studies.

Insulin Sensitivity Research (Rodent Models)

Alongside fat mass changes, some preclinical studies in obese rodent models report improvements in markers of insulin sensitivity and glucose handling following 5-Amino-1MQ administration. Researchers hypothesise that improved adipocyte NAD+/SAM status may favourably influence broader metabolic signalling, but the mechanistic link between NNMT inhibition and systemic insulin sensitivity is still being characterised and is not established in human physiology.

Absence of Human Data

It must be stated plainly and repeatedly: as of current published literature, there is no human clinical trial data of any kind for 5-Amino-1MQ. There are no registered or published human safety studies, no human pharmacokinetic data, and no human efficacy data. All evidence available for this compound is derived from rodent (mouse) in vivo studies and in vitro cell-based NNMT enzyme inhibition assays. 5-Amino-1MQ should be regarded strictly as an early-stage preclinical research tool, not a substance with any established human safety or efficacy profile.

Research Data Summary

Study / Model	Reported Effect
Diet-induced obese mouse model (NNMT inhibitor administration)	Reported reduction in fat mass and attenuated body weight gain relative to controls, without a measured decrease in food intake.
Diet-induced obese mouse model (metabolic markers)	Reported improvements in markers associated with insulin sensitivity and glucose handling in treated animals versus untreated controls.
In vitro NNMT enzyme inhibition assays	Demonstrated potent, selective inhibition of NNMT catalytic activity in cell-based and biochemical assay systems, supporting use as a chemical probe.
Adipocyte cell culture studies	Reported increases in intracellular NAD+ and SAM levels following NNMT inhibition, consistent with the proposed mechanism of action.
Human studies	None published. No human data of any kind currently exists for this compound.

Stack Combinations Studied

• 5-Amino-1MQ + NAD+ precursor compounds (e.g. NR/NMN, research context only) → Research rationale: Theoretical interest exists in combining NNMT inhibition with NAD+ precursor supplementation on the hypothesis that reduced NAD+ consumption (via NNMT blockade) plus increased NAD+ precursor availability could compound effects on cellular NAD+ status, though no dedicated combination studies have been published.

Given how early-stage this compound is in the research pipeline — with no human data and only a small body of rodent and in vitro work — very little formal stack research exists. Most discussion of combinations in this space is speculative and not derived from controlled studies.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations. No validated human dosing exists for 5-Amino-1MQ. The ranges below are loosely derived from rodent (mg/kg) research models for reference purposes only and have no established relevance to human use.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Low-Range Research Protocol	Rodent-model-derived low-dose range (mg/kg, not human-converted)	4-6 weeks (rodent studies)	Once daily (rodent studies)	Initial NNMT inhibition and NAD+/SAM pathway characterisation.
Standard Research Protocol	Rodent-model-derived mid-dose range (mg/kg, not human-converted)	6-10 weeks (rodent studies)	Once daily (rodent studies)	Fat mass and metabolic marker studies in diet-induced obese mice.
Advanced Research Protocol	Rodent-model-derived higher-dose range (mg/kg, not human-converted)	10-12 weeks+ (rodent studies)	Once daily (rodent studies)	Extended preclinical characterisation of insulin sensitivity and adiposity endpoints.

Observed Side Effects in Research

• General tolerability reported as favourable in rodent studies, with no major adverse findings described in published preclinical papers.
• No injection-site, systemic, or organ-toxicity signals have been prominently reported in the available rodent literature.

No human safety data exists for 5-Amino-1MQ. All tolerability information available is derived exclusively from rodent studies and cannot be extrapolated to human safety. This compound has not undergone the safety characterisation required before any human use consideration.

Compound Data

CAS Number

48208-26-0

Molecular Formula

C₁₀H₁₀N₂ (approximate small-molecule scaffold; may vary by salt form)

Molecular Weight

Approximately 172.2 g/mol (approximate; figures vary by salt form across suppliers)

Half-Life

Not well characterised in published literature — only rodent pharmacokinetic data exists; no human-relevant half-life data has been established

Synonyms

5-amino-1-methylquinolinium, NNMT inhibitor (research code names vary by supplier)

Research Classification

Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor

Scientific References

• [Kraus D et al. 2014] — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. — Nature — [Animal / foundational NNMT target rationale paper, genetic knockdown model, not the small-molecule inhibitor itself]
• Later chemical probe development building on this NNMT knockdown rationale characterised 5-Amino-1MQ as a small-molecule NNMT inhibitor in diet-induced obese mouse models and in vitro enzyme assays, reporting reduced fat mass and improved metabolic markers without decreased food intake. — [Animal / In vitro]

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*